Before You Buy,mucosa of the duodenum and the jejunum of the gastrointestinal tract

Gastric inhibitory peptide (GIP), also widely known as glucose-dependent insulinotropic polypeptide (GIP), is a fascinating gastrointestinal hormone with a significant impact on glucose homeostasis. Understanding its site of origin is key to comprehending its physiological functions. While the name "gastric inhibitory peptide" might suggest a gastric origin, extensive research has pinpointed its primary production sites within the upper intestinal enteroendocrine K cells. These specialized cells are predominantly found in the mucosa of the duodenum and the jejunum of the gastrointestinal tract, with a particular concentration in the duodenum and the upper jejunum.

The discovery of gastric inhibitory polypeptide dates back to the period between 1969 and 1971, a time when researchers began to recognize the influence of ingested food substances on various bodily functions. This early work laid the foundation for later identification of its specific cellular origins. These duodenal endocrine K cells are strategically positioned to detect the presence of nutrients entering the small intestine. Upon the absorption of glucose or fat, these K cells are stimulated to release GIP into the bloodstream. The release is further influenced by factors such as duodenal acidification.

Once secreted, GIP circulates in the body and exerts its effects. A critical aspect of its action involves the pancreatic β-cells. Research has shown that GIP receptors are expressed at high levels in pancreatic β-cells. Binding of GIP to these receptors leads to an increase in intracellular cyclic adenosine monophosphate (cAMP), which in turn significantly enhances glucose-stimulated insulin secretion. This makes GIP a vital component of the incretin system, a group of hormones that augment insulin release after oral nutrient intake.

Beyond its primary role in stimulating insulin secretion, GIP also influences other aspects of metabolism. Interestingly, GIP receptors are also typically found on α-cells of the endocrine pancreas, although the precise implications of this are still being investigated. Some studies suggest a role for GIP in modulating glucagon secretion, another hormone involved in glucose regulation. Furthermore, GIP protein itself is a 42-amino acid peptide, structurally related to other hormones like glucagon and secretin. The gene encoding GIP, the GIP gene, is located on Chromosome 17 (human), specifically at band 17q21.32. The GIP receptor gene, conversely, is located on Chromosome 19 (human). The GIP molecule is synthesized within the endoplasmic reticulum lumen before being secreted.

The physiological significance of GIP extends to various tissues. While its primary action is within the pancreas, GIP receptors have a broader distribution, being present in adipose tissue, heart, pituitary, and even certain brain regions. This widespread presence suggests a more multifaceted role for GIP than initially understood. The study of gastric inhibitory peptide function has evolved significantly since its discovery, moving beyond its initial characterization as a purely "gastric inhibitory" agent to recognizing its potent incretin hormone activity.

The development of understanding around GIP has been a gradual process, with significant milestones including the identification of the human GIP receptor in the late 1980s and early 1990s. Today, GIP is recognized as a crucial regulator of glucose metabolism, and its interaction with other incretins like GLP-1 (glucagon-like peptide-1) is a major area of research, particularly in the context of diabetes and metabolic disorders. The site of origin of this important hormone, the enteroendocrine K cells of the upper intestine, remains central to its physiological efficacy.